Clinical Trial Search

Primary: Percentage of Participants Failing to Meet Safety Endpoint Related to Maraviroc for Dose-Finding — 0; 0; 0; 0 percentage of participants

Primary: Change in Vaginal pH Following a Single Dose of Acidform (3, 4, and 5 g), HEC Placebo (4 g), or no Intervention. — 4.85; 4.81; 4.91; 5.00 pH

Primary: The Primary Efficacy Endpoint Was the Number of Patients Attaining Complete Response (CR) at the End of the Treatment Period (PDE Visit). — 42 Participants

Primary: Self Reported Behavioral Automaticity Index — 1.6; 4.8 score on a scale

Primary: Change From Baseline on the Analogue Rating of Tinnitus Awareness. — -4.08; -4.70; -9.82; -9.89 units on a scale — p=.04

Primary: Postprandial, Resting Muscle Protein Synthesis Rates — 0.055; 0.061 percent per hour

Primary: Change From Baseline to Week 26 in Absolute Millilitre (mL) Forced Vital Capacity (FVC) — 128.78 Milliliter (mL)

Primary: iGFR at the End of the Wash-out Period — 61.2; 61.2 ml/min/1.73 m^2 — p=0.999

Primary: Veteran's Unmet Need for Services, Satisfaction, Unmet Needs, and Quality of Life. — 71; 63; 35; 39 Participants

Primary: Number of Participants With Clinically Significant Increase in Assisting Hand Assessment (AHA) Score — 4 Participants

Primary: 10 cm Mouth Dryness Visual Analog Score — 4.51; 4.6 cm

Primary: Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16 — 95; 14 Participants — p=0.002

Primary: Change in Gait Speed — -0.49; -0.80; 5.49 m/s

Primary: 24 Hour Ambulatory Blood Pressure — -1.93; -0.64; -1.38; -1.19 mm Hg

Primary: Change From Baseline in the Total Hours of Awake Time/Day Spent in the OFF State at Week 12 — 5.17; 5.33; 4.92; 4.83 hours